May 12, 2026 01:33PM
May 11, 2026 04:01PM
Apr 2, 2026 07:01AM
Apr 2, 2026 07:00AM
Mar 10, 2026 04:01PM
Jan 15, 2026 07:05AM
May 8, 2025 04:01PM Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity
Jan 2, 2025 12:51PM
Aug 22, 2024 07:01AM
Aug 22, 2024 07:00AM
Aug 9, 2024 05:59PM
Jul 24, 2024 07:31AM
Jul 24, 2024 07:30AM
Jul 24, 2024 06:00AM Skye Bioscience Hosts Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” and Details Phase 2 Nimacimab Clinical Trial Design Including Obstructive Sleep Apnea Exploratory Endpoints
Jan 29, 2024 08:02AM
Jan 29, 2024 08:00AM
Jan 9, 2024 07:00AM
Dec 11, 2023 07:00AM
Jul 6, 2023 07:00AM
Apr 27, 2023 07:00AM
Jan 27, 2023 07:00AM Skye Bioscience Obtains Central IRB Approval for Phase 2 Clinical Trial with SBI-100 Ophthalmic Emulsion
Jan 24, 2023 08:00AM
Dec 20, 2022 07:03AM
Dec 20, 2022 07:00AM
Dec 16, 2022 07:00AM
Nov 17, 2022 07:00AM
Nov 10, 2022 10:48PM
Sep 30, 2022 03:24PM Skye Bioscience Stockholders Vote in Favor of Arrangement Agreement with Emerald Health Therapeutics, Inc.
Aug 19, 2022 03:22PM
Aug 19, 2022 02:12PM
Jul 21, 2022 07:00AM
Jul 20, 2022 07:00AM
Jun 30, 2022 07:02AM
Jun 30, 2022 07:00AM
Jan 10, 2022 07:00AM Skye Bioscience Issues Shareholder Letter Providing Progress Update and Business Outlook for 2022
Apr 22, 2021 08:30AM
Mar 16, 2021 08:30AM

322,185 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All